Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 47, Issue 3, 2007, Pages 315-322

  Modi, Nishit B ^a   Dresser, Mark ^a   Desai, Dhaval ^a   Edgar, Christopher ^b   Wesnes, Keith ^b  

^a ALZA CORPORATION   (United States)

^b CDR House ^*  (United Kingdom)

Author keywords

Cognition; Dapoxetine; Ethanol; Pharmacokinetics

Indexed keywords

ALCOHOL; DAPOXETINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; ASTHENIA; BENZYLAMINES; CENTRAL NERVOUS SYSTEM DEPRESSANTS; COGNITION; CROSS-OVER STUDIES; DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ETHANOL; HALF-LIFE; HEADACHE; HUMANS; MALE; NAPHTHALENES; NEUROPSYCHOLOGICAL TESTS; SEROTONIN UPTAKE INHIBITORS; TABLETS; VISION, LOW;

EID: 33847117706     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006297229     Document Type: Article

References (24)

1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999 ; 281: 537-544.
2. Rowland D, Perelman M, Althof S, et al. Self-reported premature ejaculation and aspects of sexual functioning and satisfaction. J Sex Med. 2004 ; 1: 225-232.
3. Rosen R, Porst H, Montorsi F. The premature ejaculation prevalence and attitudes (PEPA) survey: a multi-national survey. J Sex Med. 2004 ; 1 (suppl 1). 57-58.
4. Montague DK, Jarow J, Broderick GA, et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol. 2004 ; 172: 290-294.
5. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000 ; 85: 11-28.
6. Montejo-González AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997 ; 23: 176-194.
7. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998 ; 18: 274-281.
8. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol. 2006 ; 46: 301-309.
9. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, National Health Interview Survey, 1997-2002. Available at: http://www.cdc.gov/nchs/fastats/alcohol.htm. Accessed January 15, 2007.
10. McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000 ; 44: 1686-1690.
11. Dresser MJ, Desai D, Gidwani S, Seftel AD, Modi NB. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res. 2006 ; 18: 104-110.
12. Gibaldi M, Perrier G. Pharmacokinetics. 2nd ed. New York: Marcel Dekker ; 1982.
13. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry. 1991 ; 6: 95-102.
14. Wesnes KA, Ward T, McGinty A, Petrini O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl). 2000 ; 152: 353-361.
15. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974 ; 47: 211-218.
16. Chow S, Liu J. Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed. New York: Marcel Dekker ; 2000: 79-124.
17. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 ; 15: 657-680.
18. van Harten J, Stevens LA, Raghoebar M, Holland RL, Wesnes K, Courtnot A. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther. 1992 ; 52: 427-435.
19. Lemberger L, Rowe H, Bergstrom RF, Farid KZ, Enas GG. Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanol. Clin Pharmacol Ther. 1985 ; 37: 658-664.
20. Troy SM, Turner MB, Unruh M, Parker VD, Chiang ST. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol. J Clin Pharmacol. 1997 ; 37: 1073-1081.
21. Allen D, Lader M, Curran HV. A comparative study of the interactions of alcohol with amitriptyline, fluoxetine and placebo in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry. 1988 ; 12: 63-80.
22. Wesnes KA, Garrat C, Wickens M, Gudgeon A, Oliver S. Effects of sibutramine alone and with alcohol on cognitive function in healthy subjects. Br J Clin Pharmacol. 2000 ; 49: 110-117.
23. Pryor JL, Althof SE, Steidle C, et al. Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation: an integrated analysis of two double-blind, randomised, controlled trials. Lancet. 2006 ; 368: 929-937.
24. Linnoila M, Stapleton JM, George DT, Lane E, Eckardt MJ. Effects of fluvoxamine alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in health volunteers. J Clin Psychopharmacol. 1993 ; 13: 175-180.